At a glance
ClinicalIndex Comparison Record- ✓Initiating use of 52 mg levonorgestrel-releasing IUD for contraceptive purposes
- ✓Access to reliable cell phone and willing to respond to daily text or email messages about bleeding
- ✕Using IUD for indication other than contraception
- ✕Postpartum within 6 months, pregnant, or breastfeeding
- ✕Undiagnosed abnormal uterine bleeding prior to IUD placement
- ✕Bleeding dyscrasia
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)
In Brief
A Phase 4 clinical trial evaluating Tamoxifen and Placebo (for Tamoxifen) for Menorrhagia and 2 related conditions. Completed, enrolled 42 participants across 1 site.
Detailed Summary
This study evaluates the ability of tamoxifen to improve frequent or prolonged bleeding in new users of the 52mg levonorgestrel-releasing intrauterine device (IUD). Half of participants will receive a course of tamoxifen three weeks after insertion of the IUD, while the other half of participants will receive a course of placebo.
Study Details
Timeline
Interventions
10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
Sugar pill manufactured to mimic the tamoxifen 10mg tablet